Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes
- 26 May 2020
- journal article
- letter
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 61 (10), 2511-2514
- https://doi.org/10.1080/10428194.2020.1768380
Abstract
(2020). Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes. Leukemia & Lymphoma. Ahead of Print.This publication has 12 references indexed in Scilit:
- Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase InhibitorsClinical Lymphoma Myeloma and Leukemia, 2018
- Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trialBlood, 2018
- Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoringAmerican Journal of Hematology, 2018
- Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2017
- Ponatinib Facilitates Treatment-Free Remission By Inducing Deep Molecular ResponsesBlood, 2016
- nullPhilosophy Study, 2016
- Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid LeukemiaJournal of Oncology Practice, 2016
- Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable DiseaseJournal of Clinical Oncology, 2014
- Ponatinib in Refractory Philadelphia Chromosome–Positive LeukemiasThe New England Journal of Medicine, 2012
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2001